Sinvastatina (MK-733), novo inibidor da HMG-CoA redutase no tratamento da hipercolesterolemia do idoso com doença aterosclerótica / Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis

RESUMO

Objetivo: Avaliação da eficácia e tolerabilidade da sinvastatina, um novo e potente inibidor da HMGCoA redutase, no tratamento da hipercolesterolemia em pacientes idosos. Casuística e Métodos: Foram estudados 20 pacientes com idades entre 65 e 72 anos (x = 69 ± 3), sendo 14 mulheres e 6 homens, com colesterolemia total acima de 260 mg/dl e trigliceridemia abaixo de 350 mg/dl. Todos os pacientes apresentavam evidência clínica de doença aterosclerótica e foram observados durante 6 meses, com visitas mensais para avaliações clínica e laboratorial. A dose inicial de sinvastatina foi de 10 mg dia, ajustada a intervalos de pelo menos 4 semanas, até o máximo de 40 mg dia e mínimo de 5 mg/dia com o objetivo de manter os niveis de LDL-colesterol abaixo de 140 mg/dl. Para avaliaçao das variáveis lipídicas, foram comparadas as médias dos valores do período placebo e do período de tratamento medicamentoso...

ABSTRACT

Purpose: To evaluate the efficacy and tolerability of simvastatin, a new and potent HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients. Patients and Methods: Twenty patients,14 female and 6 male, aged 65 to 72 years (x = 69 ± 3), with total cholesterol (TC) above 260 mg/dl and triglycerides below 350 mg/dl were studied. All patients presented clinical evidences of atherosclerotic disease and were followed up for 6 months. Monthly visits were required for clinical and laboratory evaluation. The initial dosage of simvastatin was 10 mg/ day; dosage was titrated up to 10 mg/day or to a minimum of 5 mg/day in intervals of at least 4 weeks, in order to maintain LDL-cholesterol below 140 mgldl. To evaluate the changes on plasma lipid levels, the mean value of determinations during the placebo baseline period was compared to the mean value of determinations during the active treatment period...